Filing Flows › Arcus Biosciences (RCUS) › R&D spending
Arcus Biosciences (RCUS) R&D spending by quarter
Arcus Biosciences' R&D spending was $117M in Q3 2026 (third quarter 2026), +4% from Q2 2026. Over the last 6 quarters it ranged from $113M (Q2 2026) to $141M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $117M | +4% | -17% |
| Q2 2026 | $113M | -7% | — |
| Q1 2026 | $122M | +0.8% | 0% |
| Q4 2025 | $121M | -14% | — |
| Q3 2025 | $141M | +16% | — |
| Q1 2025 | $122M | — | — |
Q3 2026 at a glance
Arcus Biosciences, Q3 2026: revenue $9.0M (-65% year over year), net loss $128M, operating cash flow −$88.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arcus Biosciences' R&D spending?
Arcus Biosciences' R&D spending was $117M in Q3 2026 (third quarter 2026), +4% from Q2 2026.
How has Arcus Biosciences' R&D spending changed?
Over the last 6 quarters it ranged from $113M (Q2 2026) to $141M (Q3 2025).